Office of Clinical Trials
The Office of Clinical Trials coordinates research projects throughout Western Connecticut Health Network, at our hospitals, out-patient settings and clinical research trials with private practices in Fairfield County.
Our well-experienced, talented research team provides key assistance for many pharmaceutical-funded research trials. Our combined experience of full-time research staff includes more than 40 years of Phase I to Phase IV clinical trials, and all Clinical Research Coordinators are certified through the Association of Clinical Research Professionals (ACRP).
Clinical trials enable us to offer patients access to some of the most promising therapies available. These studies evaluate new approaches to screen for, diagnose, treat and prevent diseases. Joining a clinical trial is also a way to make a valuable contribution toward the progress against disease. Therefore, our physicians encourage their patients to enroll in clinical trials.
We are careful to follow strict guidelines to protect our patients, and to offer the best treatment options. Our Institutional Review Boards conduct an in-depth review of all clinical trials at our institution to ensure the protection of our volunteer clinical trial participants. We utilize two Institutional Review Boards, one internal and one external, to provide quality research review in a timely and efficient manner.
Our research teams are experienced, knowledgeable, detail-oriented and conscientious in conducting clinical trials. We are committed to providing compassionate and outstanding care. Areas of interest and expertise include Phase I through Phase IV clinical trials:
- Emergency Medicine
- General Surgery
- Infectious Disease
- Internal Medicine
- Interventional Cardiology
- Wound Care
Novartis CLEE011E2301: A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
S1007 (RxPONDER): Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive Breast Cancer
CALGB 80702: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Kidney S0931: EVEREST: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
E5508: Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
GO29436: A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Lung (Small Cell)
E2511: Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer
Lung (Squamous Cell)
GO29437: A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
S1400 (incl. A,B,C,D): Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
PCI-32765DBL3001: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
E3A06: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
GOG 0225: Can Diet And Exercise Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?
Please contact us with any questions you may have regarding the clinical trials at Western Connecticut Health Network.
24 Hospital Avenue
Danbury CT, 06810
Telephone: (203) 739-4551
Fax: (203) 739-6086